2015 NCCN Clinical Practice Guidelines in Oncology:Interpretation of stage IV metastatic or recurrent breast cancer
ZHENG
Xin-yu
Abstract：2015 NCCN Guidelines Insights highlight the important changes specific to the management of metastatic breast cancer in the Version 2 2015 of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. The highlights include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2) on recurrent disease. The consensus of the preferred surgical approach for most women with a local recurrence following breast-conserving therapy and sentinel node biopsy is mastectomy and a level Ⅰ/Ⅱ axillary dissection. The use of the minimally toxic endocrine therapies is preferred to the use of cytotoxic therapy whenever reasonable. The endocrine therapy could be combined with an mTOR inhibitor as a subsequent therapeutic option by considering the addition of everolimus to exemestane in women who fulfill the entry criteria of the RCT. The panel emphasized the importance of individualizing treatment strategies in patients with a recurrence of disease because of their complicated and varied treatment background.
Keywords：National Comprehensive Cancer Networkstage Ⅳ metastatic or recurrent breast cancerlocoregional surgerysystemic therapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 739-743 )